Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the efficacy and safety of quetiapine extended
release tablet versus placebo as adjunct to selective serotonin reuptake
inhibitors/serotonin/norepinephrine reuptake inhibitors (SSRI/SNRI) in the augmentation
treatment of patient with primary anxiety disorders or mood disorders with co-morbid anxiety
symptoms.